# Table of Contents

**Volume 100, Issue 2: February 2015**

## Cover Figure

Artistic view on the structure of Factor VIII.  
(image created by www.somersault1824.com)

## Editorials

143  Tumor-associated macrophages in diffuse large B-cell lymphoma  
*Robert Kridel, et al.*

145  Inherited thrombocytopenias in the era of personalized medicine  
*Patrizia Noris, et al.*

## Review Article

149  Alloantibodies to therapeutic factor VIII in hemophilia A: the role of von Willebrand factor in regulating factor VIII immunogenicity  
*Johannes Oldenburg, et al.*

## Articles

### Hematopoiesis

157  In vitro human embryonic stem cell hematopoiesis mimics MYB-independent yolk sac hematopoiesis  
*Stijn Vanhee, et al.*

### Iron Metabolism & its Disorders

167  A competitive enzyme-linked immunosorbent assay specific for murine hepcidin-1: correlation with hepatic mRNA expression in established and novel models of dysregulated iron homeostasis  
*Patrick Gutschow, et al.*

### Red Cell Biology & its Disorders

178  Dexamethasone targeted directly to macrophages induces macrophage niches that promote erythroid expansion  
*Mario Falchi, et al.*

### Coagulation & its Disorders

188  Recurrence risk after anticoagulant treatment of limited duration for late, second venous thromboembolism  
*Tom van der Hulle, et al.*

### Myelodysplastic Syndromes

194  Down-regulation of Dicer1 promotes cellular senescence and decreases the differentiation and stem cell-supporting capacities of mesenchymal stromal cells in patients with myelodysplastic syndrome  
*Youshan Zhao, et al.*

205  Validation of cytogenetic risk groups according to International Prognostic Scoring Systems by peripheral blood CD34-FISH: results from a German diagnostic study in comparison with an international control group  
*Friederike Braulke, et al.*
Acute Myeloid Leukemia

214 Characterization of gene mutations and copy number changes in acute myeloid leukemia using a rapid target enrichment protocol
Niccolò Bolli, et al.

223 In vivo and in vitro sensitivity of blastic plasmacytoid dendritic cell neoplasm to SL-401, an interleukin-3 receptor targeted biologic agent
Fanny Angelot-Delettre, et al.

231 A phase 1b/2 study of vosaroxin in combination with cytarabine in patients with relapsed or refractory acute myeloid leukemia
Jeffrey E. Lancet, et al.

Non-Hodgkin Lymphoma

238 Prognostic influence of macrophages in patients with diffuse large B-cell lymphoma: a correlative study from a Nordic phase II trial
Sari Riihijärvi, et al.

246 The NOTCH pathway is recurrently mutated in diffuse large B-cell lymphoma associated with hepatitis C virus infection
Laura Arcaini, et al.

Chronic Lymphocytic Leukemia

253 Lenalidomide interferes with tumor-promoting properties of nurse-like cells in chronic lymphocytic leukemia
Stefania Fiorcari, et al.

Plasma Cell Disorders

263 Daratumumab-mediated lysis of primary multiple myeloma cells is enhanced in combination with the human anti-KIR antibody IPH2102 and lenalidomide
Inger S. Nijhof, et al.

Stem Cell Transplantation

269 Low non-relapse mortality and long-term preserved quality of life in older patients undergoing matched related donor allogeneic stem cell transplantation: a prospective multicenter phase II trial
Didier Blaise, et al.

275 Cyclosporine and methotrexate-related pharmacogenic predictors of acute graft-versus-host disease
Isabelle Laverdière, et al.

Complications in Hematology

284 Pre-chemotherapy risk factors for invasive fungal diseases: prospective analysis of 1,192 patients with newly diagnosed acute myeloid leukemia (SEIFEM 2010-a multicenter study)
Morena Caira, et al.

Letters to the Editor

Letters are available online only at www.haematologica.org/content/100/2.toc

e42 IL-1β-releasing human acute myeloid leukemia blasts modulate natural killer cell differentiation from CD34+ precursors
Chiara Vitale, et al.
http://www.haematologica.org/content/100/2/e42

e46 JAK2, CALR, and MPL mutation spectrum in Japanese patients with myeloproliferative neoplasms
Shuichi Shirane, et al.
http://www.haematologica.org/content/100/2/e46

e49 Pharmacological targeting of β-catenin in normal karyotype acute myeloid leukemia blasts
Elizabeth A. Griffiths, et al.
http://www.haematologica.org/content/100/2/e49
The prognostic value of multiparameter flow cytometry minimal residual disease assessment in relapsed multiple myeloma
Bruno Paiva, et al.
http://www.haematologica.org/content/100/2/e53

Phase II study of bendamustine, bortezomib and dexamethasone as second-line treatment for elderly patients with multiple myeloma: the Intergroupe Francophone du Myelome 2009-01 trial
Philippe Rodon, et al.
http://www.haematologica.org/content/100/2/e56

A rare case of IGH/MYC and IGH/BCL2 double hit primary plasma cell leukemia
Anna Kalff, et al.
http://www.haematologica.org/content/100/2/e60

Health-related quality of life from the MM-003 trial of pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone in relapsed and/or refractory multiple myeloma
Kevin W. Song, et al.
http://www.haematologica.org/content/100/2/e63

Oral administration of a bone morphogenetic protein type I receptor inhibitor prevents the development of anemia of inflammation
Claire Mayeur, et al.
http://www.haematologica.org/content/100/2/e68

Extending the clinical and immunological phenotype of human interleukin-21 receptor deficiency
Polina Stepensky, et al.
http://www.haematologica.org/content/100/2/e72